

---

## Elekta's AI-powered adaptive CT-Linac, Elekta Evo, receives CE mark

STOCKHOLM – Elekta (EKTA-B.ST) announced today that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo\*, is available for sale and marketing in Europe, having received CE mark. Offering offline and online plan adaptation, as well as improved image-guided radiation therapy (IGRT) treatments, Evo enables clinicians to choose the most suitable radiation therapy technique for each cancer patient's individual case or treatment session.

“With Evo, we are emphasizing flexibility regarding how and when clinics want to implement adaptive radiation therapy (ART),” says Maurits Wolleswinkel, Elekta's President Linac and Software Solutions. “Some may prefer to continue their high throughput IGRT service and use ART for select cases and adapt plans when needed, all in one machine. Evo's range of techniques and the ability to adopt new treatments at a pace that suits a clinicians' needs have shown positive responses from our clinical research partners.”

When delivering radiation therapy, clinicians require high-quality images that enable them to visualize tumors and organs at risk to facilitate contouring. Evo addresses this need with two essential features: Iris™ high-definition, AI-enhanced imaging which allows clinicians to visualize target areas with greater clarity, and Elekta ONE Online integrated on the linac, which brings distributed treatment planning, faster dose calculation and AI-driven automation for contouring and dose planning.\*\*

Gustaf Salford, Elekta's CEO, said: “With Evo, we are making personalized, clinically effective adaptive radiation therapy treatments available to more patients. We have seen great interest in Evo from our customers and we will start installing in the coming quarters.”

For more information, visit: [elekta.com/adapt-at-your-rhythm](https://elekta.com/adapt-at-your-rhythm).

*\*Elekta Evo is CE marked with limited global availability.*

*\*\*Elekta ONE® is comprised of multiple Elekta solutions, some of which may not yet be available in all markets.*

###

### For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: [Mattias.Thorsson@elekta.com](mailto:Mattias.Thorsson@elekta.com)

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: [Raven.Canzeri@elekta.com](mailto:Raven.Canzeri@elekta.com)

Time zone: ET: Eastern Time

### About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve



---

lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.